Therapeutic effect of β-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation

Cardiovascular Research

Volumn 84, Issue 1, 2009, Pages 64-71

  Zhan, Dong Yun ^a   Morimoto, Sachio ^a   Du, Cheng Kun ^a   Wang, Yuan Yuan ^a   Lu, Qun Wei ^b   Tanaka, Atsushi ^a   Ide, Tomomi ^a   Miwa, Yoshikazu ^a   Takahashi Yanaga, Fumi ^a   Sasaguri, Toshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Blocker; Dilated cardiomyopathy; Sudden death; Survival; Ventricular fibrillation

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; TROPONIN; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; HEART DISEASE; HEART MUSCLE; HEART VENTRICLE FIBRILLATION; LIPOPHILICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; THERAPY EFFECT; ANIMAL; DISEASE MODEL; DRUG EFFECT; ELECTROCARDIOGRAPHY; GENETICS; HEART LEFT VENTRICLE FUNCTION; MUTATION; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATENOLOL; CARBAZOLES; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; METOPROLOL; MICE; MUTATION; PROPANOLAMINES; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 70449717089     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp168     Document Type: Article

References (42)

1. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564-1575.
2. Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baughman KL. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994;23:586-590.
3. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VVet al. Prevalence and etiology of idiopathic dilated cardiomyo-pathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol 1992;69:1458-1466.
4. Fatkin D, Graham RM. Molecular mechanisms of inherited cardiomyopa-thies. Physiol Rev 2002;82:945-980.
5. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardi-ovasc Res 2008;77:659-666.
6. Mogensen J, Murphy RT, Shaw T, Bahl A, Redwood C, Watkins H et al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2004;44:2033-2040.
7. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B et al. Mutations in sarcomere protein genes as a cause of dilated cardio-myopathy. N Engl J Med 2000;343:1688-1696.
8. Hanson EL, Jakobs PM, Keegan H, Coates K, Bousman S, Dienel NH et al. Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyo-pathy. J Card Fail 2002;8:28-32.
9. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 2007;101:185-194.
10. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980; 44:117-133. (Pubitemid 10000987)
11. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134-142. (Pubitemid 10000988)
12. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563.
13. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-490.
14. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
15. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101:378-384.
16. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-2080.
17. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-546.
18. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopa-thy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-1446.
19. Andersson B, Hamm C, Persson S, Wikstrom G, Sinagra G, Hjalmarson A et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol 1994;23: 1397-1404.
20. Andersson B, Caidahl K, di Lenarda A, Warren SE, Goss F, Waldenstrom A et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardi-omyopathy. Circulation 1996;94:673-682.
21. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355. (Pubitemid 26152713)
22. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687.
23. Chizzola PR, Freitas HF, Caldas MA, da Costa JM, Meneghetti C, Marinho NV et al. Effects of carvedilol in heart failure due to dilated car-diomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study). Arq Bras Cardiol 2000;74:233-242.
24. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-2651.
25. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of meto-prolol versus carvedilol. Circulation 2000;102:546-551.
26. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metopro-lol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
27. Potter EK. Inspiratory inhibition of vagal responses to baroreceptor and chemoreceptor stimuli in the dog. J Physiol 1981;316:177-190.
28. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-2217.
29. Nakaura H, Morimoto S, Yanaga F, Nakata M, Nishi H, Imaizumi T et al. Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy. Am J Physiol 1999;277:C225-C232.
30. Rundell VL, Geenen DL, Buttrick PM, de Tombe PP. Depressed cardiac tension cost in experimental diabetes is due to altered myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol 2004;287: H408-H413.
31. Ablad B, Bjuro T, Bjorkman JA, Edstrom T. Prevention of ventricular fibrillation requires central beta-adrenoceptor blockade in rabbits. Scand Car-diovasc J 2007;41:221-229.
32. Di Lenarda A, De Maria R, Gavazzi A, Gregori D, Parolini M, Sinagra G et al. Long-term survival effect of metoprolol in dilated cardiomyopathy. The SPIC (Italian Multicentre Cardiomyopathy Study) Group. Heart 1998;79:337-344.
33. Patrianakos AP, Parthenakis FI, Mavrakis HE, Diakakis GF, Chlouverakis GI, Vardas PE. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J 2005;150:985.
34. Nishioka K, Nakagawa K, Umemura T, Jitsuiki D, Ueda K, Goto C et al. Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy. Heart 2007;93:247-248.
35. Neglia D, De Maria R, Masi S, Gallopin M, Pisani P, Pardini S et al. Effects of long-term treatment with carvedilol on myocardial blood flow in idio-pathic dilated cardiomyopathy. Heart 2007;93:808-813.
36. Remme WJ, Torp-Pedersen C, Cleland JG, Poole-Wilson PA, Metra M, Komajda M et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007;49:963-971.
37. Karle CA, Kreye VA, Thomas D, Rockl K, Kathofer S, Zhang W et al. Anti-arrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001;49:361-370.
38. Kawakami K, Nagatomo T, Abe H, Kikuchi K, Takemasa H, Anson BD et al. Comparison of HERG channel blocking effects of various beta-blockers-implication for clinical strategy. Br J Pharmacol 2006;147:642-652.
39. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-1362.
40. Neil-Dwyer G, Bartlett J, McAinsh J, Cruickshank JM. Beta-adrenoceptor blockers and the blood-brain barrier. Br J Clin Pharmacol 1981;11: 549-553.
41. Leenen FH. Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circ Res 2007;101:221-223.
42. Gourine A, Bondar SI, Spyer KM, Gourine AV. Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart. Circ Res 2008;102:633-636.